Inovio files 8-K; Q3 2025 financial results furnished as Exhibit 99.1

Rhea-AI Filing Summary

Inovio Pharmaceuticals (INO) filed an 8-K stating it furnished a press release announcing financial results for the quarter ended September 30, 2025. The release is attached as Exhibit 99.1.

Per Item 2.02 and General Instruction B.2, this information is being furnished and is not deemed filed under the Exchange Act. The report is dated November 10, 2025 and was signed by CFO Peter Kies.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0001055726FALSE00010557262025-11-102025-11-10

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 10, 2025

Inovio Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-14888

33-0969592

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

660 W. Germantown Pike Suite 110

Plymouth Meeting, PA 19462

(Address of principal executive offices, including zip code)

(267) 440-4200

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.001 par value

INO

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Item 2.02    Results of Operations and Financial Condition.

On November 10, 2025, Inovio Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2025. A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated by reference herein.

In accordance with General Instruction B.2 of Form 8-K, the information in this Item 2.02 and Exhibit 99.1 hereto are being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing by the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.

Item 9.01    Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number
99.1			Press Release, dated November 10, 2025 (filed herewith)
104			Cover Page Interactive Data File (formatted as inline XBRL).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INOVIO PHARMACEUTICALS, INC.

Date: November 10, 2025

By:

/s/ Peter Kies

Peter Kies

Chief Financial Officer

FAQ

What did INO disclose in this 8-K?

The company furnished a press release announcing financial results for the quarter ended September 30, 2025, attached as Exhibit 99.1.

Which item of the 8-K applies to INO’s update?

Item 2.02, Results of Operations and Financial Condition.

Is the information considered filed with the SEC?

No. Under General Instruction B.2, the Item 2.02 information and Exhibit 99.1 are furnished and not deemed filed under the Exchange Act.

When was the announcement made?

The company reported the update on November 10, 2025.

Where can I find the financial results details?

In the press release attached as Exhibit 99.1 to the 8-K.

Who signed the 8-K for INO?

It was signed by Peter Kies, Chief Financial Officer.

What is Inovio’s trading symbol and exchange?

The common stock trades on Nasdaq under the symbol INO.